Medicon Hellas S.A.
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems. It al… Read more
Medicon Hellas S.A. (MEDIC) - Net Assets
Latest net assets as of December 2022: €16.95 Million EUR
Based on the latest financial reports, Medicon Hellas S.A. (MEDIC) has net assets worth €16.95 Million EUR as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.81 Million) and total liabilities (€14.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €16.95 Million |
| % of Total Assets | 53.3% |
| Annual Growth Rate | 21.45% |
| 5-Year Change | 75.12% |
| 10-Year Change | N/A |
| Growth Volatility | 13.13 |
Medicon Hellas S.A. - Net Assets Trend (2014–2022)
This chart illustrates how Medicon Hellas S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medicon Hellas S.A. (2014–2022)
The table below shows the annual net assets of Medicon Hellas S.A. from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €16.95 Million | +18.19% |
| 2021-12-31 | €14.34 Million | +30.08% |
| 2020-12-31 | €11.03 Million | +7.51% |
| 2019-12-31 | €10.26 Million | +5.95% |
| 2018-12-31 | €9.68 Million | +23.52% |
| 2017-12-31 | €7.84 Million | +28.07% |
| 2016-12-31 | €6.12 Million | +14.52% |
| 2015-12-31 | €5.34 Million | +49.17% |
| 2014-12-31 | €3.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medicon Hellas S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1349960700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.80 Million | 57.79% |
| Common Stock | €6.98 Million | 41.19% |
| Other Components | €173.10K | 1.02% |
| Total Equity | €16.95 Million | 100.00% |
Medicon Hellas S.A. Competitors by Market Cap
The table below lists competitors of Medicon Hellas S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SCG Construction JSC
VN:SCG
|
$23.90K |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
$23.90K |
|
216400
KO:216400
|
$23.94K |
|
EDINBURGH WORLDW. LS-01
F:2TI
|
$23.95K |
|
Sauer Energy Inc
PINK:BFYW
|
$23.82K |
|
Luceco plc
LSE:LUCE
|
$23.82K |
|
Gillette Pakistan Ltd
KAR:GLPL
|
$23.78K |
|
Montaka Global Long Only Equites Fund (Managed Fund)
AU:MOGL
|
$23.76K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicon Hellas S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 14,344,460 to 16,953,400, a change of 2,608,940 (18.2%).
- Net income of 2,533,130 contributed positively to equity growth.
- Dividend payments of 106,410 reduced retained earnings.
- Other factors increased equity by 182,220.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.53 Million | +14.94% |
| Dividends Paid | €106.41K | -0.63% |
| Other Changes | €182.22K | +1.07% |
| Total Change | €- | 18.19% |
Book Value vs Market Value Analysis
This analysis compares Medicon Hellas S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.98x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €2.50 | €2.44 | x |
| 2021-12-31 | €3.25 | €2.44 | x |
| 2022-12-31 | €3.84 | €2.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicon Hellas S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.94%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.20%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.88x
- Recent ROE (14.94%) is below the historical average (18.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 21.28% | 6.34% | 0.38x | 8.73x | €370.71K |
| 2015 | 33.76% | 14.62% | 0.37x | 6.25x | €1.18 Million |
| 2016 | 19.05% | 8.96% | 0.39x | 5.39x | €553.80K |
| 2017 | 21.92% | 13.52% | 0.41x | 3.91x | €933.92K |
| 2018 | 18.91% | 13.29% | 0.51x | 2.81x | €862.22K |
| 2019 | 7.56% | 5.76% | 0.47x | 2.78x | €-250.54K |
| 2020 | 6.86% | 4.96% | 0.53x | 2.59x | €-346.16K |
| 2021 | 21.20% | 14.14% | 0.69x | 2.17x | €1.61 Million |
| 2022 | 14.94% | 12.20% | 0.65x | 1.88x | €837.79K |
Industry Comparison
This section compares Medicon Hellas S.A.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $52,966,000
- Average return on equity (ROE) among peers: 16.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicon Hellas S.A. (MEDIC) | €16.95 Million | 21.28% | 0.88x | $23.83K |
| Lavipharm S.A (LAVI) | $52.97 Million | 16.96% | 1.37x | $80.56 Million |